LAFOV-Lung PET

2026-525834-45-00 Human pharmacology (Phase I) - First administration to humans Authorised, recruitment pending

Status Authorised, recruitment pending · 1 EU/EEA countries · 1 sites

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Authorised, recruitment pending
Participants planned 41
Countries 1
Sites 1

Investigation in healthy volunteers

Key facts

Sponsor
Medical University Of Vienna
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
Decision date (initial)
2026-06-29
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Investigation in healthy volunteers

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Medical University Of Vienna

Sponsor organisation
Medical University Of Vienna
Address
Spitalgasse 23, Alsergrund Alsergrund
City
Vienna
Postcode
1090
Country
Austria

Scientific contact point

Organisation
Medical University Of Vienna
Contact name
Department of Clinical Pharmacology

Public contact point

Organisation
Medical University Of Vienna
Contact name
Department of Clinical Pharmacology

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Austria Authorised, recruitment pending 41 1
Rest of world 0

Investigational sites

Austria

1 site · Authorised, recruitment pending
Medical University Of Vienna
Department of Clinical Pharmacology, Waehringer Guertel 18-20, Alsergrund, Vienna

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2026-03-16 Austria Acceptable
2026-06-22
2026-06-29